- Home
- Publications
- Publication Search
- Publication Details
Title
PI3K in cancer–stroma interactions: bad in seed and ugly in soil
Authors
Keywords
-
Journal
ONCOGENE
Volume 33, Issue 24, Pages 3083-3090
Publisher
Springer Nature
Online
2013-07-29
DOI
10.1038/onc.2013.265
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Lack of Estrogen Receptor- Is Associated with Epithelial-Mesenchymal Transition and PI3K Alterations in Endometrial Carcinoma
- (2013) E. Wik et al. CLINICAL CANCER RESEARCH
- Fibroblast Growth Factor 2 Induces E-Cadherin Down-Regulation via PI3K/Akt/mTOR and MAPK/ERK Signaling in Ovarian Cancer Cells
- (2013) Man-Tat Lau et al. PLoS One
- PI3-Kinase γ Promotes Rap1a-Mediated Activation of Myeloid Cell Integrin α4β1, Leading to Tumor Inflammation and Growth
- (2013) Michael C. Schmid et al. PLoS One
- Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
- (2013) L. M. Coussens et al. SCIENCE
- PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances
- (2012) Lomon So et al. BIOCHEMICAL JOURNAL
- Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells
- (2012) L. Zhang et al. BLOOD
- Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
- (2012) Taru Muranen et al. CANCER CELL
- Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
- (2012) Douglas Hanahan et al. CANCER CELL
- IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma
- (2012) Ju-Hee Lee et al. CANCER LETTERS
- HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis
- (2012) Hyunseung Lee et al. CANCER LETTERS
- Oncogenic PI3K Mutations Lead to NF- B-Dependent Cytokine Expression following Growth Factor Deprivation
- (2012) J. E. Hutti et al. CANCER RESEARCH
- Mesenchymal stem cell signaling in cancer progression
- (2012) Anja Torsvik et al. CANCER TREATMENT REVIEWS
- An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
- (2012) L. A. Byers et al. CLINICAL CANCER RESEARCH
- Targeting the PI3K signaling pathway in cancer therapy
- (2012) Chandra Bartholomeusz et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells
- (2012) Areumnuri Kim et al. LEUKEMIA RESEARCH
- Endothelial PI3K-C2α, a class II PI3K, has an essential role in angiogenesis and vascular barrier function
- (2012) Kazuaki Yoshioka et al. NATURE MEDICINE
- Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes
- (2012) Jeffrey J. Wallin et al. PLoS One
- PI3Kδ Is Essential for Tumor Clearance Mediated by Cytotoxic T Lymphocytes
- (2012) Eva Maria Putz et al. PLoS One
- Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110 (PIK3CA)
- (2012) J. E. Burke et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cancer stem cells and epithelial–mesenchymal transition: Concepts and molecular links
- (2012) Christina Scheel et al. SEMINARS IN CANCER BIOLOGY
- Akt/PKB-Mediated Phosphorylation of Twist1 Promotes Tumor Metastasis via Mediating Cross-Talk between PI3K/Akt and TGF-β Signaling Axes
- (2012) Gongda Xue et al. Cancer Discovery
- Does the PI3K pathway promote or antagonize regulatory T cell development and function?
- (2012) Dalya R. Soond et al. Frontiers in Immunology
- Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome Gefitinib-resistance in non-small cell lung cancer cell lines
- (2011) H Li et al. Advances in Medical Sciences
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
- (2011) J. Hoellenriegel et al. BLOOD
- Receptor Tyrosine Kinases and TLR/IL1Rs Unexpectedly Activate Myeloid Cell PI3Kγ, A Single Convergent Point Promoting Tumor Inflammation and Progression
- (2011) Michael C. Schmid et al. CANCER CELL
- PIK3R1 (p85 ) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer
- (2011) M. E. Urick et al. CANCER RESEARCH
- Immunotherapy with PI3K Inhibitor and Toll-Like Receptor Agonist Induces IFN- +IL-17+ Polyfunctional T Cells That Mediate Rejection of Murine Tumors
- (2011) N. A. Marshall et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Distinct Effects of Leukocyte and Cardiac Phosphoinositide 3-Kinase γ Activity in Pressure Overload–Induced Cardiac Failure
- (2011) Federico Damilano et al. CIRCULATION
- Modulation of the Tumor Microvasculature by Phosphoinositide-3 Kinase Inhibition Increases Doxorubicin Delivery In Vivo
- (2011) N. Qayum et al. CLINICAL CANCER RESEARCH
- Phosphatidylinositol 3-Kinase Isoforms as Novel Drug Targets
- (2011) Karolina Blajecka et al. CURRENT DRUG TARGETS
- Present and Future of PI3K Pathway Inhibition in Cancer: Perspectives and Limitations
- (2011) E. Ciraolo et al. CURRENT MEDICINAL CHEMISTRY
- CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies
- (2011) Jorge J Castillo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Inhibition of Matrix Metalloproteinase 14 (MMP-14)-mediated Cancer Cell Migration
- (2011) Kevin Zarrabi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Phosphorylation of CSF-1R Y721 mediates its association with PI3K to regulate macrophage motility and enhancement of tumor cell invasion
- (2011) N. G. Sampaio et al. JOURNAL OF CELL SCIENCE
- Tumor angiogenesis: molecular pathways and therapeutic targets
- (2011) Sara M Weis et al. NATURE MEDICINE
- Local treatment of metastatic cancer—killing the seed or disturbing the soil?
- (2011) Scott C. Morgan et al. Nature Reviews Clinical Oncology
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Extracellular Matrix Degradation and Remodeling in Development and Disease
- (2011) P. Lu et al. Cold Spring Harbor Perspectives in Biology
- Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP
- (2010) Seaho Kim et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- PI3K inhibition in inflammation: Toward tailored therapies for specific diseases
- (2010) Alessandra Ghigo et al. BIOESSAYS
- Key Role of Phosphoinositide 3-Kinase Class IB in Pancreatic Cancer
- (2010) C. E. Edling et al. CLINICAL CANCER RESEARCH
- PI3K/Akt Signalling Pathway Specific Inhibitors: A Novel Strategy to Sensitize Cancer Cells to Anti-Cancer Drugs
- (2010) Marco Falasca CURRENT PHARMACEUTICAL DESIGN
- The catalytic PI3K isoforms p110γ and p110δ contribute to B cell development and maintenance, transformation, and proliferation
- (2010) Sandra Beer-Hammer et al. JOURNAL OF LEUKOCYTE BIOLOGY
- The emerging mechanisms of isoform-specific PI3K signalling
- (2010) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- A biochemical mechanism for the oncogenic potential of the p110 catalytic subunit of phosphoinositide 3-kinase
- (2010) H. A. Dbouk et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PIKing the right isoform: the emergent role of the p110β subunit in breast cancer
- (2010) Silvia Carvalho et al. VIRCHOWS ARCHIV
- Myeloid Cells in the Tumor Microenvironment: Modulation of Tumor Angiogenesis and Tumor Inflammation
- (2010) Michael C. Schmid et al. Journal of Oncology
- Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofibroblasts differentially via superoxide production in a PI3Kγ-dependent manner
- (2009) Ahmed E. Awad et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
- (2009) Yongping Crawford et al. CANCER CELL
- Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- (2009) W. Wang et al. CLINICAL CANCER RESEARCH
- Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor
- (2009) Dexin Kong et al. EUROPEAN JOURNAL OF CANCER
- Cancer associated fibroblasts (CAFs) in tumor microenvironment
- (2009) Fei Xing Frontiers in Bioscience-Landmark
- Phosphatidylinositol 3-Kinase γ Inhibition Ameliorates Inflammation and Tumor Growth in a Model of Colitis-Associated Cancer
- (2009) Ana González–García et al. GASTROENTEROLOGY
- Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9
- (2009) Jing-song Chen et al. HEPATOLOGY RESEARCH
- The p110 Isoform of Phosphatidylinositol 3-Kinase Controls Susceptibility to Leishmania major by Regulating Expansion and Tissue Homing of Regulatory T Cells
- (2009) D. Liu et al. JOURNAL OF IMMUNOLOGY
- Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment
- (2009) Zachary T. Schafer et al. NATURE
- Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation
- (2009) H. B. Salvesen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Leukemic challenge unmasks a requirement for PI3K in NK cell-mediated tumor surveillance
- (2008) E. Zebedin et al. BLOOD
- A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity
- (2008) J. R. Garlich et al. CANCER RESEARCH
- Regulation of Cancer Cell Survival, Migration, and Invasion by Twist: AKT2 Comes to Interplay
- (2008) G. Z. Cheng et al. CANCER RESEARCH
- Effects of the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 on the Tumor Vasculature: Implications for Clinical Imaging
- (2008) C. R. Schnell et al. CANCER RESEARCH
- Overlapping and distinct roles for PI3Kβ and γ isoforms in S1P-induced migration of human and mouse endothelial cells
- (2008) Regine Heller et al. CARDIOVASCULAR RESEARCH
- Genetic and Pharmacological Targeting of Phosphoinositide 3-Kinase-γ Reduces Atherosclerosis and Favors Plaque Stability by Modulating Inflammatory Processes
- (2008) Anne Fougerat et al. CIRCULATION
- Phosphatidylinositol-3-Kinase-γ Is Integral to Homing Functions of Progenitor Cells
- (2008) Emmanouil Chavakis et al. CIRCULATION RESEARCH
- The tumor microenvironment and its contribution to tumor evolution toward metastasis
- (2008) Girieca Lorusso et al. HISTOCHEMISTRY AND CELL BIOLOGY
- Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration
- (2008) Mariona Graupera et al. NATURE
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
- Class I PI3K in oncogenic cellular transformation
- (2008) L Zhao et al. ONCOGENE
- Class 1A PI3K regulates vessel integrity during development and tumorigenesis
- (2008) T. L. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phosphoinositide 3-Kinase p110 Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development
- (2008) E. Ciraolo et al. Science Signaling
- Phosphoinositide 3-Kinase γ Gene Knockout Impairs Postischemic Neovascularization and Endothelial Progenitor Cell Functions
- (2007) Paolo Madeddu et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started